Psyence BioMed Achieves Major Natural Ibogaine HCl Production Milestone and Reports Strong Financial Position

Psyence Biomedical Ltd. (Nasdaq: PBM), a biopharmaceutical company focused on nature‑derived psychedelic therapeutics, announced that it successfully produced **GMP‑compliant natural ibogaine hydrochloride (Ibogaine HCl)** — a key pharmaceutical‑grade form of ibogaine derived from ethically sourced African plant material — marking a significant scientific and manufacturing milestone. This achievement underscores the company’s vertically integrated strategy and enhances its capacity to support clinical and therapeutic development. Ibogaine HCl’s conversion into a stable crystalline salt increases purity, dosing accuracy, solubility, and overall suitability for regulated medical research and development. Psyence BioMed also reported a strong financial position, with $12 million in cash and zero debt, and highlighted that its Phase 2b psilocybin clinical trial is underway as it enters 2026 well positioned to advance its strategic priorities. In corporate governance news, the company announced a change to its Board of Directors: Christopher Bull resigned as a director and has been replaced by Graham Patrick, an attorney experienced in governance, compliance, and cross‑border management — a valuable addition given Psyence’s international operations. Psyence BioMed is one of the few vertically integrated psychedelic biotech firms publicly traded on Nasdaq, dedicated to addressing unmet mental health needs by developing nature‑derived psilocybin and ibogaine medicines. #PsyenceBioMed #IbogaineHCl #BiotechNews #PsychedelicMedicine #SlimScan #GrowthStocks #CANSLIM